Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-17T12:16:54.346Z Has data issue: false hasContentIssue false
  • English
  • Français

Anti-tumour necrosis factor therapy is associated with certain subtypes of chronic rhinosinusitis

Published online by Cambridge University Press:  28 April 2016

C G Leonard ,
C Masih ,
S McDonald ,
G Taylor ,
N Maiden  and
P J Leyden
C G Leonard*
Affiliation:
Department of Otorhinolaryngology, Craigavon Area Hospital, Northern Ireland, UK
C Masih
Affiliation:
Department of Rheumatology, Craigavon Area Hospital, Northern Ireland, UK
S McDonald
Affiliation:
Department of Rheumatology, Craigavon Area Hospital, Northern Ireland, UK
G Taylor
Affiliation:
Department of Otorhinolaryngology, Craigavon Area Hospital, Northern Ireland, UK
N Maiden
Affiliation:
Department of Rheumatology, Craigavon Area Hospital, Northern Ireland, UK
P J Leyden
Affiliation:
Department of Otorhinolaryngology, Craigavon Area Hospital, Northern Ireland, UK
*
Address for correspondence: Mr C G Leonard, Department of Otorhinolaryngology, Level 3 Secretary's Office, Craigavon Area Hospital, Craigavon, Northern Ireland, UK E-mail: mrcgleonard@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Chronic rhinosinusitis has many risk factors; however, the effect of anti-tumour necrosis factor therapy has not been investigated in depth. Our experience points to a detrimental clinical effect in overall prevalence of chronic rhinosinusitis, despite its benefit in certain subtypes.

Method:

A telephone survey was performed to parallel the findings of the Global Allergy and Asthma European Network chronic rhinosinusitis screening survey. This was itself based on the widely recognised European Position Paper on Rhinosinusitis and Nasal Polyps criteria.

Results:

A total of 120 patients responded to the survey. The prevalence of chronic rhinosinusitis in the anti-tumour necrosis factor therapy population was 20 per cent (95 per cent confidence interval = 12.84–27.16). When compared using a chi-square test, for a two-by-two contingency table, this finding was significant against the prevalence recorded in the normal population.

Conclusion:

This is the first observational study indicating increased prevalence of chronic rhinosinusitis in patients treated with anti-tumour necrosis factor therapy. These clinical findings require investigation in greater depth to clarify the nature of pathologies currently diagnosed and treated as chronic rhinosinusitis.

Keywords

RhinitisRhinitis, Allergic, NonseasonalParanasal Sinus DiseaseParanasal SinusesRheumatoid ArthritisAnkylosing Spondylitis
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 130 , Issue 6 , June 2016 , pp. 560 - 564
Copyright
Copyright © JLO (1984) Limited 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Smith, KA, Orlandi, RR, Rudmik, L. Cost of adult chronic rhinosinusitis: a systematic review. Laryngoscope 2015;125:1547–56Google Scholar
2 Fokkens, WJ, Lund, VJ, Mullol, J, Bachert, C, Alobid, I, Baroody, F et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012;50:1–12 CrossRefGoogle ScholarPubMed
3 Kato, A. Immunopathology of chronic rhinosinusitis. Allergol Int 2015;64:121–30CrossRefGoogle ScholarPubMed
4 Hastan, D, Fokkens, WJ, Bachert, C, Newson, RB, Bislimovska, J, Bockelbrink, A et al. Chronic rhinosinusitis in Europe – an underestimated disease. A GA2LEN study. Allergy 2011;66:1216–23CrossRefGoogle ScholarPubMed
5 Bhattacharyya, N, Lee, LN. Evaluating the diagnosis of chronic rhinosinusitis based on clinical guidelines and endoscopy. Otolaryngol Head Neck Surg 2010;143:147–51CrossRefGoogle ScholarPubMed
6 Karosi, T, Csomor, P, Sziklai, I. Tumour necrosis factor-α receptor expression correlates with mucosal changes and biofilm presence in chronic rhinosinusitis with nasal polyposis. Laryngoscope 2012;122:504–10CrossRefGoogle ScholarPubMed
7 Doran, M, Crowson, C, Pond, G, O'Fallon, W, Gabriel, S. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287–93Google Scholar
8 Ding, T, Ledingham, J, Lugmani, R, Westlake, S, Hyrich, K, Lunt, M et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49:2217–19CrossRefGoogle ScholarPubMed
9 Maroon, M, Bond, U, Phelan, M. Sinusitis: a possible link with adalimumab. Clin Rheumatol 2008;27:1189–90Google Scholar
10 Tezuka, H, Abe, Y, Iwata, M, Takeuchi, H, Ishikawa, H, Matsushita, M et al. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature 2007;448:929–33CrossRefGoogle ScholarPubMed